{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:35:37Z","timestamp":1789731337470,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.autrev.2008.04.010","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T07:40:11Z","timestamp":1209886811000},"page":"501-507","source":"Crossref","is-referenced-by-count":56,"title":["Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders"],"prefix":"10.1016","volume":"7","author":[{"given":"Frauke","family":"Neff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"N\u00f6lker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2008.04.010_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.1.110304.100113","article-title":"Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications","volume":"1","author":"Skovronsky","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.autrev.2008.04.010_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","article-title":"Active and passive immunotherapy for neurodegenerative disorders","volume":"31","author":"Brody","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.autrev.2008.04.010_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1471-4159.2006.04365.x","article-title":"Autoantibodies to alpha-synuclein in inherited Parkinson's disease","volume":"101","author":"Papachroni","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.autrev.2008.04.010_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","article-title":"Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals","volume":"37","author":"Weksler","year":"2002","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.autrev.2008.04.010_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.57.5.801","article-title":"Reduced levels of amyloid \u00df-peptide antibody in Alzheimer's disease","volume":"57","author":"Du","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2008.04.010_bib6","article-title":"Human anti-prion protein antibodies block A117V PrP peptide fibril formation and prevent A117V PrP peptide-induced neurotoxicity","volume":"33","author":"Wei","year":"2007","journal-title":"Abstr Soc Neurosci"},{"key":"10.1016\/j.autrev.2008.04.010_bib7","series-title":"The mosaic of autoimmunity","first-page":"53","article-title":"Natural autoimmunity","author":"Shoenfeld","year":"1989"},{"key":"10.1016\/j.autrev.2008.04.010_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/156720506775697098","article-title":"Has the amyloid cascade hypothesis for AD been proved?","volume":"3","author":"Hardy","year":"2006","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.autrev.2008.04.010_bib9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nrn938","article-title":"Amyloid-beta immunotherapy for AD: the end of the beginning","volume":"3","author":"Schenk","year":"2002","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.autrev.2008.04.010_bib10","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/brain\/awg191","article-title":"Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity","volume":"126","author":"Du","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2008.04.010_bib11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","article-title":"Intravenous immunoglobulins containing antibodies against \u00df-amyloid for the treatment of Alzheimer's disease","volume":"75","author":"Dodel","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2008.04.010_bib12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","article-title":"Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system","volume":"27","author":"Bell","year":"2007","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.autrev.2008.04.010_bib13","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-Ab antibody alters CNS and plasma A\u00df clearance and decreases brain Ab burden in a mouse model of AD","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2008.04.010_bib14","unstructured":"N.R. Relkin P. Szabo B. Adamiak 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging in press."},{"key":"10.1016\/j.autrev.2008.04.010_bib15","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1007\/s00018-007-7217-5","article-title":"Physiological and pathological properties of alpha-synuclein","volume":"64","author":"Tofaris","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.autrev.2008.04.010_bib16","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1523\/JNEUROSCI.19-14-05782.1999","article-title":"Alpha-synuclein shares physical and functional homology with 14-3-3 proteins","volume":"19","author":"Ostrerova","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.autrev.2008.04.010_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0896-6273(95)90040-3","article-title":"Characterization of a novel protein regulated during the critical period for song learning in the zebra finch","volume":"15","author":"George","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.autrev.2008.04.010_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.autrev.2008.04.010_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0161-813X(02)00067-0","article-title":"Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease","volume":"23","author":"Uversky","year":"2002","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.autrev.2008.04.010_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"Alpha-synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat Cell Boil"},{"key":"10.1016\/j.autrev.2008.04.010_bib21","doi-asserted-by":"crossref","first-page":"47746","DOI":"10.1074\/jbc.M408906200","article-title":"Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation","volume":"279","author":"Hodara","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2008.04.010_bib22","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1021\/bi030086j","article-title":"Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease","volume":"42","author":"Volles","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.autrev.2008.04.010_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"Faseb J"},{"key":"10.1016\/j.autrev.2008.04.010_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","article-title":"Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease","volume":"64","author":"Masliah","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2008.04.010_bib25","first-page":"1132","article-title":"Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity","volume":"368","author":"Emadi","year":"2007","journal-title":"Biol"},{"key":"10.1016\/j.autrev.2008.04.010_bib26","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1073\/pnas.0400569101","article-title":"Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease","volume":"101","author":"Benner","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2008.04.010_bib27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro1492","article-title":"Pathogenesis of prion diseases: current status and future outlook","volume":"4","author":"Aguzzi","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.autrev.2008.04.010_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0404.2007.00868.x","article-title":"Prion proteins: a biological role beyond prion diseases","volume":"116","author":"Hu","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2008.04.010_bib29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archneur.63.4.497","article-title":"Emerging pharmacotherapies for Creutzfeldt\u2013Jakob disease","volume":"63","author":"Korth","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2008.04.010_bib30","doi-asserted-by":"crossref","first-page":"9295","DOI":"10.1073\/pnas.151242598","article-title":"Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody","volume":"98","author":"Enari","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2008.04.010_bib31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35089090","article-title":"Antibodies inhibit prion propagation and clear cell cultures of prion infectivity","volume":"412","author":"Peretz","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2008.04.010_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nature01457","article-title":"Monoclonal antibodies inhibit prion replication and delay the development of prion disease","volume":"422","author":"White","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2008.04.010_bib33","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1111\/j.1742-4658.2007.05919.x","article-title":"Therapeutic approaches for prion and AD","volume":"274","author":"Wisniewski","year":"2007","journal-title":"FEBS J"},{"key":"10.1016\/j.autrev.2008.04.010_bib34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1126\/science.1063093","article-title":"Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies","volume":"294","author":"Heppner","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.autrev.2008.04.010_bib35","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1742-4658.2007.05721.x","article-title":"Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells","volume":"274","author":"Handisurya","year":"2007","journal-title":"Febs J"},{"key":"10.1016\/j.autrev.2008.04.010_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(03)00907-8","article-title":"Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent","volume":"350","author":"Schwarz","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.autrev.2008.04.010_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14760584.6.2.153","article-title":"Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies","volume":"6","author":"Bade","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.autrev.2008.04.010_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1742-4658.2006.05629.x","article-title":"Prions and prion diseases","volume":"274","author":"Beekes","year":"2007","journal-title":"FEBS J"},{"key":"10.1016\/j.autrev.2008.04.010_bib39","doi-asserted-by":"crossref","first-page":"11320","DOI":"10.1074\/jbc.M412441200","article-title":"Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations","volume":"280","author":"Fioriti","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2008.04.010_bib40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/(SICI)1097-4547(19981101)54:3<331::AID-JNR4>3.0.CO;2-K","article-title":"Prion protein-overexpressing cells show altered response to a neurotoxic prion protein peptide","volume":"54","author":"Brown","year":"1998","journal-title":"J Neurosci Res"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997208000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997208000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T02:07:45Z","timestamp":1557540465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997208000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1568997208000451"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2008.04.010","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}